Alkem Laboratories Ltd has announced the acquisition of two companies – Adroit Biomed, a dermatology and cosmetology-focused firm, and Bombay Ortho Industries, a medical technology company.
The acquisitions will strengthen Alkem’s position in high-growth therapeutic segments. They will also boost its manufacturing capabilities in the orthopedic implant sector.
Strengthening Dermatology and Cosmetology Portfolio
Alkem will acquire Adroit Biomed for ₹140 crore, with payments made in two tranches. The deal is expected to close by April 1.
Adroit Biomed, which recorded a turnover of ₹53.55 crore in FY24, will help Alkem expand its dermatology and cosmetology product range. Additionally, Adroit’s strong market reach and omni-channel presence will support Alkem’s growth in this segment.
Expanding in the Orthopedic Implant Sector
Alkem will also acquire Bombay Ortho Industries for ₹147 crore, payable in four tranches. The acquisition is set to be completed by June 30.
Established in 2021, Bombay Ortho specializes in hip and knee implants—key segments in India’s rapidly growing medical device industry.
Alkem views this investment as a strategic move to strengthen its manufacturing capabilities and leverage Bombay Ortho’s expertise in orthopedic implants.
Leadership’s Perspective on the Acquisitions
Alkem Chairman B.N. Singh stated, “The acquisition of Adroit will diversify our portfolio, enhance market penetration, and strengthen our position in the dermatology and cosmetology segments. Our investment in Bombay Ortho aligns with our Medtech strategy in India”.
Alkem’s Managing Director, Sandeep Singh added, “Medtech is expanding rapidly in India, and there is a high demand for quality implants. Through these acquisitions, we aim to address this growing need and strengthen our position in the medical devices market”.
As reported by livemint.com, Alkem Laboratories continues to expand its footprint in key healthcare segments through strategic acquisitions. This reinforces its commitment to innovation and growth.
